One more completed stock market debut and 2021 will have officially matched last year with the highest number of biopharma IPOs on record, and amounts collected through venture capital financings have now risen to the top as well.
LONDON – Microbiome specialist Enterobiotix Ltd. closed a $21.5 million series A to advance development of its live bacteria fecal transplant drug pipeline.
Locate Bio Ltd. has closed a £10 million (US$13.8 million) funding round co-led by investors Mercia Asset Management and BGF to advance its orthobiologics product pipeline. The Nottingham, U.K.-based startup, which spun out from the University of Nottingham’s School of Pharmacy, is hoping to disrupt the orthobiologics market with its drug releasing, bone grafting products.
PERTH, Australia – On the heels of a A$90 million (US$67.12 million) initial public offering on the Australian Securities Exchange, device company Trajan Group Holdings Ltd. has doubled its share price and is well poised for its next stage of global growth. Trajan makes precision consumable products, devices and solutions that used in analyzing biological samples.
Med-tech firms raising money in public or private financings, including: Centaur Diagnostics, Paramit, Seventh Sense Biosystems, Tecan, Yourbio Health.
Health-tech startup Doctor Anywhere Ltd. (DA) has raised $88 million in series C fundraising, as the telehealth sector continues to be attractive for investors. The round is one of the largest private investments ever raised by a Southeast Asian digital health company and was led by growth equity investor Asia Partners. Novo Holdings, Philips, OSK-SBI Venture Partners, EDBI, Square Peg, IHH Healthcare, Kamet Capital and Pavilion Capital also participated.
RSS
